Navigation Links
VIRxSYS Presents Data on HIV Vaccine at Keystone HIV Vaccine Symposia
Date:3/28/2008

HIV-Based Lentiviral vector VRX1023 Shows Promising Results

GAITHERSBURG, Md., March 28 /PRNewswire/ -- VIRxSYS Corporation will present initial scientific data for VRX1023 today at the Keystone Symposia Conference in Banff, Alberta. VRX1023 is part of a new vaccine approach -- using HIV-based lentivector as vector boost. VRX1023, an HIV antigen expressing lentiviral vector, has produced positive results in mice and in preliminary non-human primate studies. A larger, confirmatory study in Rhesus Macaques has been initiated.

"VRX1023 shows exciting promise," says Dr. Franck Lemiale, Director of Research and Development, Immunobiology for VIRxSYS. "The results from these mouse studies are very encouraging. We have seen significant long term response against HIV proteins both in terms of cellular immunity, which is mediated by T Lymphocytes, and humoral immunity, which is mediated by antibodies."

VIRxSYS takes a different approach as anti-HIV vaccine than recently publicized failed vaccines. The company is using an engineered HIV-based lentiviral vector to deliver the vaccinating antigens. In small animals, the VRX1023 lentivector has induced long-lasting cellular and humoral response against HIV. Using a DNA prime/vector boost strategy, VIRxSYS has obtained with VRX1023 greater anti-HIV immune responses than with other viral vector boost approaches currently used in the clinic, including adenoviral vectors similar to those that have been extensively tested in patients.

The ultimate goal for an anti-HIV vaccine is to suppress the impact of the initial infection, thereby significantly slowing the process of the disease. Due to the properties of the virus, a traditional total sterilizing goal may not be achievable for an anti-HIV vaccine. The next step would be to a prophylactic vaccine, which would reduce the impact of hyper-viremia in the first weeks of the infection. The aim of this vaccine is to suppress initial viremia, prevent
'/>"/>

SOURCE VIRxSYS
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/8/2008)...ocus on Use of Pro-Healing Stent with AMI Patie...t Therapy, HONG KONG, May 8 /- Twelv...t study and the real-world registry use of OrbusNe...irst pro-healing stent, will be,presented next wee...in., The symposium, titled "Clinical Impact of th...
(Date:5/8/2008)...ewswire-FirstCall/ -- AstraZeneca (NYSE:,AZN) toda...rug Application,(sNDA) to the U.S. Food and Drug A...e fumarate) Extended-Release Tablets to seek appro...der (GAD), including maintenance of,antianxiety ef...t for an,atypical antipsychotic medicine in GAD. T...
(Date:5/8/2008)...irstCall/ -- Go Healthy (Pink Sheets: GOHE),announ... Cholesterade (R),in three medical settings with a...in 6 centers around the country. Dr. William Bryan... Hospital in the Texas Medical Center,will coordin... Team,Physician for the Houston Astros and the for...
(Date:5/7/2008)...eferred Induction Dosing Regimen, SEATTLE, May 7 ...Inc.,(Nasdaq: TRBN ) today announced that its par...NYSE: WYE ), has commenced patient dosing in the ...s with rheumatoid arthritis,(RA). In collaboration...,TRU-015, SBI-087 and other CD20-directed products...
Breaking Medicine Technology:Data from Randomized Pilot Study, Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008 2AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 2AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 4AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 5AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 6AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 7AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 8Go Healthy Initiates Additional Clinical Tests on Cholesterade 2Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 2Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 3Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 4Cell Therapeutics Inc 28CTI 29 Invest Northwest Presentation to be Webcast 4026 1Reducing HD risk naturally post menopause 14530 1Reducing HD risk naturally post menopause 14530 2Winners Announced in HopeLabs Global Competition to Get Kids Moving 21 14529 1Winners Announced in HopeLabs Global Competition to Get Kids Moving 21 14529 2Winners Announced in HopeLabs Global Competition to Get Kids Moving 21 14529 3Winners Announced in HopeLabs Global Competition to Get Kids Moving 21 14529 4Winners Announced in HopeLabs Global Competition to Get Kids Moving 21 14529 5NutraCea Appoints New Chief Financial Officer 14528 1NutraCea Appoints New Chief Financial Officer 14528 2NutraCea Appoints New Chief Financial Officer 14528 3
...une 3, 2007 - Genmab A/S (CSE: GEN) announced,toda...uMax-EGFr™ (zalutumumab) antibody may have b...several types of EGFr (epidermal,growth factor rec...r the signaling ability,of EGFr have been identifi...ions may be a critical factor in the potential suc...
...ADT, Germany, June 4, 2007 – Data presented,...nical Oncology,(ASCO) meeting in Chicago show that...squo;s oral 5-fluorouracil (5-FU) therapy UFT,(teg...an excellent,response rate in the first-line treat...the SCOUT study (Study of CPT-11 with Oxaliplatin ...
Other Medicine Technology:Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an,Important Treatment Option for Patients With Metastatic Colorectal,Cancer 2Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an,Important Treatment Option for Patients With Metastatic Colorectal,Cancer 3
(Date:5/11/2008).../ -- The winners of today,s Susan G.,Komen Pittsbu...lace Overall Winners Male: Pat McGuire, Char...lbein, Pittsburgh, Pa., 19:19, 2nd Place Overall ...e: Anna Beck, Washington, Pa., 19:22, 3rd Place ...h, Pa., 16:13 Female: Jessica Winter, Pittsb...
(Date:5/11/2008)...s, Caregivers Call for Better Care,Better Regulat... -- Families visiting their,loved ones at more tha...,across the nation this Mother,s Day will receive ... advocates. The effort asks family members to call...benstein to demand better,care. In addition, famil...
(Date:5/10/2008).../ -- Children,s Hospital of Pittsburgh of,UPMC is ...he-art hospital,campus., (Photo: http://www.news...e new Children,s Hospital opens in May 2009, it wi... The new hospital building will,serve as the cente... is,situated on a 10-acre campus. Located in the L...
(Date:5/9/2008)...for Maintenance Treatment for ADHD, INDIANAPOLIS,...pany,(NYSE: LLY ) announced today that the United...roved Strattera(R) (atomoxetine HCI) for,maintenan...sorder (ADHD) in,children and adolescents. Stratte... is the first FDA-approved non-stimulant to treat ...
Breaking Medicine News(10 mins):Health News:16th Annual Komen Pittsburgh Race for the Cure(R) Winners Announced 2Health News:Advocates Make Mother's Day Push for Quality Care 2Health News:ONE YEAR Until the New Children's Hospital of Pittsburgh of UPMC Opens in Lawrenceville 2Health News:ONE YEAR Until the New Children's Hospital of Pittsburgh of UPMC Opens in Lawrenceville 3Health News:ONE YEAR Until the New Children's Hospital of Pittsburgh of UPMC Opens in Lawrenceville 4Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 2Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 3Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 4Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 5Health News:FDA Approves Strattera(R) for Maintenance of ADHD in Children and Adolescents 6
...o a latest report published in Archives of Otolary... be attributed// to psychiatric or neurologic cond...5 men and women who had suffered dizziness for an ...re in the age group of 15 to 89. It was found that...
...re may be smiling. Researchers have given their op... caesarian operations//, those decided solely upon... According to their results published in the Cana...isks encountered by a woman who opts for a C-secti...
...urgeons has determined that by modifying a classic...such as baseball players//, to their prior level o... medial collateral ligament (MCL), which links and...er arm where they meet at the elbow. Less trauma...
... of targeted anti-cancer drugs that blocks the hum...hows promise// in prolonging the lives of patients...i study shows. The drug, a molecular targeted comp...nhibiting the function of HER2 receptors, interrup...
Other Medicine News:Health News:Modified Ligament Surgery Improves Outcomes Players, Athletes 2Health News:Modified Ligament Surgery Improves Outcomes Players, Athletes 3Health News:New Drugs Shows Promise in Slowing the Progression of Prostate Cancer 2Health News:New Drugs Shows Promise in Slowing the Progression of Prostate Cancer 3
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
Medicine Products: